{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:32:04Z","timestamp":1784194324946,"version":"3.55.0"},"reference-count":36,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2004]]},"abstract":"Owing to the predominance of gram-positive pathogens in neutropenic cancer patients, newer generation quinolones with an expanded gram-positive spectrum and enhanced potency, may have a role to play for prophylaxis and\/or empiric therapy in such patients. The in vitro activity of gatifloxacin was compared with that of ciprofloxacin, levofloxacin and trovafloxacin against 848 recent clinical isolates from cancer patients. Against gram-positive organisms, gatifloxacin was the most active agent tested inhibiting all A<i>erococcus, Listeria monocytogens, Micrococcus, Stomatococcus mucilaginous, Bacillus<\/i>, and <i>Rhodococcus equi<\/i> strains at \u22642 mg\/l, its designated susceptibility breakpoint. It was also very active against methicillin-susceptible staphylococci and <i>Streptococcus<\/i> spp. (including penicillin nonsusceptible <i>Streptococcus pneumoniae<\/i> and viridans streptococci). It had moderate activity against methicillin-resistant staphylococci and <i>Enterococcus faecalis<\/i>, inhibiting 68\u201380% of these strains at \u22642 mg\/l. Gatifloxacin also had good activity against the Enterobacteriaceae (although ciprofloxacin was more potent) inhibiting >95% of isolates at \u22641 mg\/l. Nonfermentative gram-negative organisms were less susceptible to all 4 agents. Gatifloxacin was very active against <i>Acinetobacter <\/i><i>lwoffi<\/i> (MIC<sub>100<\/sub> 0.12 mg\/l) and had moderate activity against <i>Acinetobacter baumanii<\/i>, <i>Chryseobacterium<\/i> spp., <i>Stenotrophomonas maltophilia<\/i>, <i>Pseudomonas aeruginosa<\/i> and other <i>Pseudomonas<\/i> species. <i>Alcaligenes xylosoxidans<\/i> strains were relatively resistant to all 4 agents.<\/jats:p>","DOI":"10.1159\/000081708","type":"journal-article","created":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T13:50:20Z","timestamp":1099317020000},"page":"214-220","source":"Crossref","is-referenced-by-count":14,"title":["In vitro Antimicrobial Activity of Gatifloxacin Compared with Other Quinolones against Clinical Isolates from Cancer Patients"],"prefix":"10.1159","volume":"50","author":[{"given":"Kenneth V.I.","family":"Rolston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Vaziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Frisbee-Hume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Streeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2004,11,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2886%2990510-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1086%2F598620"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819930601%2971%3A11%3C3640%3A%3AAID-CNCR2820711128%3E3.0.CO%3B2-H"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9343%2899%2980367-2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002%2F%28SICI%291097-0142%2819990701%2986%3A1%3C126%3A%3AAID-CNCR18%3E3.0.CO%3B2-1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F39.suppl_2.15"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1086%2F520155"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F45.4.437"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2802%2900433-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097%2F00019048-199805000-00012"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.94.25.13991"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1006%2Ftaap.1997.8183"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkf152"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2165%2F00003495-200262010-00002"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1086%2F314054"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2FS0924-8579%2800%2900222-3"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkf028"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2802%2900506-0"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159%2F000077284"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.48.4.1400-1401.2004"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2803%2900152-4"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F44.2.295"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2898%2900150-3"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.44.8.2211-2213.2000"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F45.3.363"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016%2FS0924-8579%2802%2900239-X"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2801%2900332-7"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.45.9.2486-2494.2001"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007%2Fs100960050312"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1469-0691.1999.tb00439.x"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1086%2F520247"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1086%2F339215"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2899%2900010-3"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkf211"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1159%2F000069786"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016%2FS0732-8893%2803%2900158-5"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:46:51Z","timestamp":1745466411000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000081708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000081708","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}